Galectin Therapeutics is a brand dedicated to helping patients with NASH cirrhosis and cancer. They strive to provide innovative therapies that can improve the lives of individuals suffering from chronic liver disease and cancer. Their lead drug, GR-MD-02 (belapectin), is a galectin-3 inhibitor that targets and fights inflammatory, fibrotic, and malignant diseases.

Galectin Therapeutics aims to combat NASH cirrhosis, a severe and life-threatening condition that currently lacks a cure. Through their development programs, they work towards finding effective treatments for this disease and other related conditions. In addition, they focus on cancer immunotherapy, utilizing galectin-3 inhibition to enhance the body's immune system in targeting and eliminating cancer cells.

With their efforts, Galectin Therapeutics brings hope to the more than 115 million people worldwide affected by NASH, offering potential solutions and advancements in the field of liver disease and cancer treatment